Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin

Abstract Background Cisplatin, mitomycin C and anthracyclines demonstrate high activity in BRCA1-deficient tumors. This study aimed to evaluate the efficacy of the triplet combination of these drugs in BRCA1-driven high-grade serous ovarian carcinomas (HGSOCs). Methods Ten HGSOC patients with germ-l...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Tatiana V. Gorodnova, Anna P. Sokolenko, Khristina B. Kotiv, Tatiana N. Sokolova, Alexandr O. Ivantsov, Konstantin D. Guseynov, Ekaterina A. Nekrasova, Olga A. Smirnova, Igor V. Berlev, Evgeny N. Imyanitov
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2021-02-01
coleção:	Hereditary Cancer in Clinical Practice
Assuntos:	Ovarian cancer BRCA1 Neoadjuvant chemotherapy Cisplatin Mitomycin C Doxorubicin
Acesso em linha:	https://doi.org/10.1186/s13053-021-00173-2
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!